- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03808571
Cord Blood Nesfatin-1 and Irisin in the Intrauterine Growth Restricted Fetuses
January 17, 2019 updated by: erbil karaman, Yuzuncu Yıl University
The Association of Cord Blood Nesfatin-1 and Irisin Level With Fetal Doppler Parameters in Pregnancies Complicated With Intrauterine Growth Restricted Fetuses
: The aim of this study is to investigate Cord blood irisin and nesfatin-1 levels in pregnancies with intrauterine growth retardation and to determine whether they are associated with abnormal fetal doppler findings or not.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
This study was conducted at Yüzüncü Yıl University Medical Faculty Obstetrics and Gynecology Clinic.
The study group included 34 pregnant women ranged from 18 to 45 years old who have intrauterine growth retardation and underwent ceseraen section.
32 pregnant women who had no abnormality on prenatal follow-up and underwent elective ceserean seciton served as control group.
The maternal age, height, weight, body mass index (BMI), systolic and diastolic blood pressures were recorded in both groups of patients.
Maternal serum total blood count and biochemical parameters were obtained from the laboratory parameters.
Gestational week at birth, birth weight, sex, 1st and 5th minute APGAR scores were recorded.
Blood samples were collected from all the cases during the cesarean section for measurmenet of nesfatin-1 and irisin by doubly clamped umbilical cord.
Blood samples were immediately centrifuged in sterile tubes and maintained at -80 ° C until assessed.
Study Type
Observational
Enrollment (Actual)
66
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Van, Turkey, 65000
- Yuzuncu Yil University, Medical faculty, department of obstetric and gynecology
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 45 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
Pregnant women
Description
Inclusion Criteria:
- Pregnant women with intrauterine grwoth rectricted fetuses.
- Healthy pregnancies
Exclusion Criteria:
- Pregnant women with chronic medical conditions
- multiple pregnancies
- fetuses with fetal malfomations or genetic syndromes
- pregnant women older than 45 years old
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Observational Models: Case-Control
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Study group
Pregnancies complicated with intrauterine growth restricted fetuses
|
The cord blood will be taken during the delivery of baby.
|
Control group
Healthy pregnancies
|
The cord blood will be taken during the delivery of baby.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
cord blood nesfatn-1 level measurement
Time Frame: 9 months
|
cord blood levels of nesfatin-1 in pregnancies with intrauterine growth restricted fetuses and healthy pregnancies.
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cord blood irisin level measurement
Time Frame: 9 months
|
ord blood levels of irisin in pregnancies with intrauterine growth restricted fetuses and healthy pregnancies.
|
9 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
January 1, 2018
Primary Completion (Actual)
January 10, 2019
Study Completion (Actual)
January 15, 2019
Study Registration Dates
First Submitted
January 16, 2019
First Submitted That Met QC Criteria
January 16, 2019
First Posted (Actual)
January 17, 2019
Study Record Updates
Last Update Posted (Actual)
January 22, 2019
Last Update Submitted That Met QC Criteria
January 17, 2019
Last Verified
January 1, 2019
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 1
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Nesfatin-1
-
Istanbul Medeniyet UniversityUnknownObesity | Insulin Resistance | Type 2 Diabetes | Nesfatin-1Turkey
-
Merck Sharp & Dohme LLCRecruitingNon-small Cell Lung Cancer | Solid Tumors | Programmed Cell Death-1 (PD1, PD-1) | Programmed Cell Death 1 Ligand 1(PDL1, PD-L1) | Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)Japan
-
SanionaCompleted
-
Calliditas Therapeutics ABEurofins Optimed; York Bioanalytical SolutionCompleted
-
Calliditas Therapeutics ABCompleted
-
Rambam Health Care CampusIsrael Science FoundationCompleted
-
Alvotech Swiss AGCompleted
-
PfizerCompleted
-
CONRADNational Institute of Allergy and Infectious Diseases (NIAID); Eunice Kennedy... and other collaboratorsCompletedPharmacokinetics of 1% Tenofovir Gel Following Coitus | Pharmacodynamics of 1% Tenofovir Gel Following CoitusUnited States
-
JKT Biopharma Co., Ltd.Recruiting
Clinical Trials on cord blood specimen during the delivery
-
Centre Hospitalier Universitaire de BesanconNot yet recruitingPerineal Tear | Perineum; Rupture | Perineum; Tear
-
University of RochesterTerminated
-
Timothy J Nelson, MD, PhDMayo Clinic; Children's Hospital of Philadelphia; Children's Hospital Colorado; University of Oklahoma and other collaboratorsCompletedHypoplastic Left Heart SyndromeUnited States
-
Uppsala UniversityUmeå University; Halmstad County Hospital; County Council of Halland, SwedenCompletedIron Deficiency | Developmental DelaySweden
-
Walid El-NaggarUnknown
-
Dokuz Eylul UniversityCompletedPain | Anxiety State | Fear | Child, OnlyTurkey
-
University Hospital, BordeauxCompletedPremature Delivery
-
University Hospital, BordeauxRecruiting
-
PfizerCompleted
-
Assistance Publique Hopitaux De MarseilleCompletedRespiratory Distress SyndromeFrance